basophils. We focused on relationship of specific basophil reactivity in relationship to proportion of regulatory T cells. Methods: Forty-five patients with history of systemic symptoms of allergy to Hymenoptera venom were included. Basophil reactivity before the treatment and after one year of allergen immunotherapy (AIT) was measured by CD63 expression, CD203c marker used for basophil identification. Cells were stimulated by aqueous solution of allergen in concentration range 0.01 to 1 mg/mL. T regulatory cells were identified as CD4 positive, CD25 bright and CD127 negative at the same interval of treatment. Monoclonal antibodies conjugated with fluorochromes were used, measured by FACSCalibur. Paired t test and correlation analysis used for statistical evaluation. Results: Median Treg proportion before therapy was 2.160, after IT 1.960, basophil specific response (proportion of CD63 positive cells) at the same interval were 3.65 and 4.11 at 0.01 mg/mL, 13.1 and 16.1 for 0.1 mg/mL and 33.85 and 40.8 for 1 mg/mL. All differences were not statistically significant. Differences of basophil activation were not significantly related to proportion of T regulatory cells. Conclusions: In our group of patients with HV allergy, treated by AIT, we did not found any relationship between basophil specific activation during allergen immunotherapy and proportion of T regulatory cells. Background: Up to 3% of the general population suffers from potentially lifethreatening systemic reactions after honeybee and wasp stings. Unfortunately, there are still individuals who have a convincing history of an anaphylactic event, but lack the necessary diagnostic, making difficult the decision for immunotherapy. Our aims were to evaluate the feasibility of using recombinant allergens in the Basophil activation test (BAT) for the diagnosis of Hymenoptera allergy and to develop a high-throughput diagnostic device combining the advantages of basophil activation tests with a panel of recombinant allergens: rVes v 1, rVes v 2, rVes v 3, rVes v 5, rApi m 1, rApi m 2, rApi m 3 and rApi m 5. Methods: Basophil activation test (BAT) and measurement of specific IgE was performed on 47 wasp venom, 14 Honeybee venom allergic patients and 17 healthy controls. Specificity and sensitivity of BAT performed with recombinant His-tag purified wasp venom allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5, recombinant honeybee venom allergens Api m 1, Api m 2, Api m 3 and Api m 5 and commercial extracts have been compared. Each patient had a history of grade I or II anaphylaxis after an insect sting. All patient sera were collected before initiation of SIT. Results: BAT performed with the panel of recombinant allergens markedly increased the specificity and the sensitivity in the detection of wasp venom allergic subjects. Conclusions: Basophil activation test provides a valuable new in vitro method for the detection of allergy to wasp venom and may supplement routine tests for allergy diagnosis in problematic cases. Recombinant allergens might help to dissect relevant allergens for basophil degranulation. Allergy & Respiratory Diseases, Universita Degli Studi Di Genova, Genoa, Italy. Background: The standard venom immunotherapy involves the administration of the maintenance dose every 4 to 6 weeks. This regimen may have compliance problem especially in the long term, thus extended intervals have been proposed. We prospectively compared the efficacy of 3-or 4-month extended maintenance dose and the conventional regimen. Methods: Patients receiving immunotherapy of a single venom were offered the delayed maintenance dose, and were then followed-up for field re-stings. Only the re-stings by the insect for which the patients received immunotherapy were considered. A matched group of patients receiving the conventional maintenance were used for comparison, by univariate and multivariate analysis. Results: Fifty-two patients (44 male, 8 female, mean age 52 years) were certainly re-stung on 113 occasions by the insect for which they were receiving immunotherapy. 90 re-stings occurred during the 3-month maintenance and 23 during the 4-month maintenance. The control group, on conventional protocol with one single venom, included 103 patients (79 male, 24 female, mean age 41 years) certainly re-stung on 160 occasions by the specific insect. The rate of re-sting without reaction was 97% in the delayed maintenance and 82% in the conventional group with a significant difference in favour of the former (P ¼ 0.01). None of the variables considered resulted predictive for systemic reactions by logistic regression analysis Conclusions: The delayed maintenance dose approach is al least as effective and safe as the conventional one. The 4-month maintenance seems to be the best option in term of convenience and economic save. Background: Cytotoxic T lymphocyte associated gene-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be downregulated by immunotherapy. We assessed the effects on CTLA4 of venom immunotherapy given by different induction protocols (classic, rush or ultra rush). Methods: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. In the classical regimen, the induction lasted 6 weeks, in the rush protocol it lasted 3 days, and in the ultra-rush maintenance was achieved in 24 hours. Soluble IL-10 was assayed in the same samples for comparison. CTLA-4 and IL10 were measured by commercial immuoassays. Results: Seventy-six patients (52 male, mean age 35 years) were studied. Of them, 30 underwent the classic induction, 22 the rush and 24 the ultra rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction in all groups, thus irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, the same behaviour was observed with IL-10 that significantly increased at the end of the induction.
Background: Up to 3% of the general population suffers from potentially lifethreatening systemic reactions after honeybee and wasp stings. Unfortunately, there are still individuals who have a convincing history of an anaphylactic event, but lack the necessary diagnostic, making difficult the decision for immunotherapy. Our aims were to evaluate the feasibility of using recombinant allergens in the Basophil activation test (BAT) for the diagnosis of Hymenoptera allergy and to develop a high-throughput diagnostic device combining the advantages of basophil activation tests with a panel of recombinant allergens: rVes v 1, rVes v 2, rVes v 3, rVes v 5, rApi m 1, rApi m 2, rApi m 3 and rApi m 5. Methods: Basophil activation test (BAT) and measurement of specific IgE was performed on 47 wasp venom, 14 Honeybee venom allergic patients and 17 healthy controls. Specificity and sensitivity of BAT performed with recombinant His-tag purified wasp venom allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5, recombinant honeybee venom allergens Api m 1, Api m 2, Api m 3 and Api m 5 and commercial extracts have been compared. Each patient had a history of grade I or II anaphylaxis after an insect sting. All patient sera were collected before initiation of SIT. Results: BAT performed with the panel of recombinant allergens markedly increased the specificity and the sensitivity in the detection of wasp venom allergic subjects. Conclusions: Basophil activation test provides a valuable new in vitro method for the detection of allergy to wasp venom and may supplement routine tests for allergy diagnosis in problematic cases. Recombinant allergens might help to dissect relevant allergens for basophil degranulation. Allergy & Respiratory Diseases, Universita Degli Studi Di Genova, Genoa, Italy. Background: The standard venom immunotherapy involves the administration of the maintenance dose every 4 to 6 weeks. This regimen may have compliance problem especially in the long term, thus extended intervals have been proposed. We prospectively compared the efficacy of 3-or 4-month extended maintenance dose and the conventional regimen. Methods: Patients receiving immunotherapy of a single venom were offered the delayed maintenance dose, and were then followed-up for field re-stings. Only the re-stings by the insect for which the patients received immunotherapy were considered. A matched group of patients receiving the conventional maintenance were used for comparison, by univariate and multivariate analysis. Results: Fifty-two patients (44 male, 8 female, mean age 52 years) were certainly re-stung on 113 occasions by the insect for which they were receiving immunotherapy. 90 re-stings occurred during the 3-month maintenance and 23 during the 4-month maintenance. The control group, on conventional protocol with one single venom, included 103 patients (79 male, 24 female, mean age 41 years) certainly re-stung on 160 occasions by the specific insect. The rate of re-sting without reaction was 97% in the delayed maintenance and 82% in the conventional group with a significant difference in favour of the former (P ¼ 0.01). None of the variables considered resulted predictive for systemic reactions by logistic regression analysis Conclusions: The delayed maintenance dose approach is al least as effective and safe as the conventional one. The 4-month maintenance seems to be the best option in term of convenience and economic save. Background: Cytotoxic T lymphocyte associated gene-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be downregulated by immunotherapy. We assessed the effects on CTLA4 of venom immunotherapy given by different induction protocols (classic, rush or ultra rush). Methods: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. In the classical regimen, the induction lasted 6 weeks, in the rush protocol it lasted 3 days, and in the ultra-rush maintenance was achieved in 24 hours. Soluble IL-10 was assayed in the same samples for comparison. CTLA-4 and IL10 were measured by commercial immuoassays. Results: Seventy-six patients (52 male, mean age 35 years) were studied. Of them, 30 underwent the classic induction, 22 the rush and 24 the ultra rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction in all groups, thus irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, the same behaviour was observed with IL-10 that significantly increased at the end of the induction.
Conclusions: Soluble CTLA-4 is a useful immunological marker of the effect of immunotherapy for hymenoptera allergy. From an immunologic point of view, there is no difference among the various protocol of induction. Background: Between 9.3 and 28.5% of world population are estimated to be allergic to the protein components of Hymenoptera venom and among them, the hyaluronidase (HYAL) is one of the most important, although the nature of its IgE binding epitopes is unknown. Methods: Enzyme was purified from P. paulista venom by cation exchange chromatography in AKTA-FPLC system with a Hiprep CM FF column. Fractions with HYAL activity were pooled, lyophilized, dialyzed against distilled water in presence of protease inhibitor (PMSF) and subjected to SDS-PAGE 15%. The only protein bands visualized were submitted to tryptic digestion and to MALDI-ToF/ToF mass spectrometry. Digested peptides produced were compared with partial/complete protein sequences from Data Bank including with the HYAL (Q9U6V9) of Polistes annularis venom used as model. Western blotting was performed with Pp-HYAL-specific antibody to test the identity of pure protein.
Results: All analysis performed identified the pure protein as an HYAL present in P.paulista venom, which also had its cDNA sequence (GI:302201582) cloned and determined in previous studies, being its high similarity with the Polistes annularis enzyme already confirmed. The mature allergenic protein has 338 amino acids and a molecular weight of 39 KDa. The same allergen is known in other insects, venoms and immunological cross reactivity may sometimes be observed among closely related species. Here, the immunoblotting assay revealed that the Pp-HYAL-specific antibody used recognized the correspondent protein in the purified fraction and in the crude venom of P. paulista, but not in the Apis mellifera and Solenopsis invicta venoms. Conclusions: The methodology used was able to purify the allergen, which is a key step in the characterization of its binding epitopes. Such knowledge has direct implications in accuracy of diagnostic procedures and strategies for specific immunotherapy of allergic patients to the venom of this insect. Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Background: Induction of long-term tolerance towards Phl p 5 was previously achieved by transplantation of hematopoetic stem cells (HSCs) genetically modified to express membrane-bound Phl p 5 allergen. To facilitate the further development of tolerogenic cell therapies for allergy, a transgenic mouse expressing Phl p 5 ubiquitously as membrane-anchored protein, was generated. Here we investigated the immunogenicity of the membrane-anchored version of Phl p 5. Methods: The Phl p 5-transgenic mouse (Balb/c background) was generated by pronuclear injection integrating Phl p 5 fused to a leader peptide and a transmembrane domain under control of a CMV-promotor with a GFPreporter. Splenocytes (2.5 · 10 6 per mouse), cell extracts containing mainly membrane proteins and recombinant (r) Phl p 5 [5 mg1/2 Al(OH) 3 per mouse] were injected subcutaneously into naïve Balb/c mice (n ¼ 8 per group). The amount of Phl p 5 of splenocytes and cell extracts was semiquantitatively determined via western blotting. Furthermore skin of Phl p 5-transgenic mice was grafted onto naïve Balb/c (n ¼ 13 in 2 independent experiments), a rejection model in allo-transplantation since skin is highly immunogenic and therefore readily rejected. Phl p 5-specific antibody response was determined in sera by ELISAs. For T-cell responses splenocyte-proliferation was assessed in vitro after stimulation with rPhl p 5. Results: Surprisingly, a prompt rejection (within 8-10 days) was elicited, accompanied by a strong Phl p 5 specific antibody response including Phl p 5-specific IgE in wildtype Balb/c after skin rejection of Phl p 5-transgenic mice. Additionally to the skin grafted group, mice receiving splenocytes or rPhl p 5 plus adjuvant showed a comparable response in matters of Phl p 5-specific IgE-and IgG1-levels through the whole follow-up (week 1, 2, 3, 5, 7, 9, 11) suggesting an unusually strong immune response to cell or tissue-bound Phl p 5. Furthermore Phl p 5-specific IgG2a/2b/3, IgA and IgM were induced. Besides in vitro splenocyte-proliferation assays showed Phl p 5 specific T-cell responses in all groups of mice that showed strong humoral responses. Background: Only a limited number of proteins have the potential to induce Th2-polarized immune responses and specific IgE in genetically predisposed individuals. However, why the contact with an allergen results either in allergic sensitization or tolerance induction has remained unclear so far. Here, we focused on the in depth study of uptake, induction of signal transduction pathways, and gene regulation in monocyte-derived dendritic cells (MoDCs) of allergic and normal individuals in response to the major birch pollen (BP) allergen Bet v 1.0101 and its structural homolog from celery, Api g 1.0101. Methods: Live cell fluorescence microscopy was used to analyze uptake kinetics, competitive binding, and internalization pathways of labeled allergens by iMoDCs. To delineate allergen-mediated gene activation, iMoDCs were incubated with the allergens, a control stimulus, or left untreated followed by real-time PCR-based gene expression profiling. Surface-bound IgE was detected by immunofluorescence microscopy and IgE-mediated gene activation by real-time PCR. Results: Comparable kinetics of Bet v 1.0101 and Api g 1.0101 uptake were observed for both allergic and healthy donors. In competititve binding assays, however, Bet v 1.0101 outcompeted Api g 1.0101 for surface recognition in both donor groups. Pharmacological inhibition evidenced that Bet v 1.0101 internalization occurred in a receptor-mediated manner showing characteristics of lipid raft-dependent endocytosis. MoDCs of both donor groups were IgE positive and showed marked upregulation in NF-kB dependent genes after Fce receptor activation by anti-IgE. Bet v 1.0101-stimulation, in contrast, exclusively triggered transcription of the Th2 cytokines IL-4 and IL-13
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